BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Change in the number of shares and votes in BioArctic AB (publ)

Tue, Oct 31, 2017 18:00 CET

Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has increased during the month of October due to the new share issue carried out in connection with the listing of BioArctic’s B-share on Nasdaq Stockholm. A total of 25,000,000 B-shares have been added. At October 31, 2017 the number of A-shares, each representing ten (10) votes, amounts to 14,399,996 and the number of B-shares, each representing one (1) vote, amounts to 73,659,989. The total number of votes thus amounts to 217,659,

There are no items matching the current filter

There are no more items matching the current filter

Back to top

About Us

Change in the number of shares and votes in BioArctic AB (publ)

Subscribe

Media

Share

About Us

Change in the number of shares and votes in BioArctic AB (publ)

Subscribe

Media